Obesity Pharmacotherapy 2025: Advances and Remaining Challenges

Review of obesity pharmacotherapy advancements and challenges covers GLP-1/GIP drugs, emerging agents, access barriers, and the evolving treatment landscape.

Alotaibi, Saqer S et al.·Experimental and therapeutic medicine·2025·Strong EvidenceReview
RPEP-09897ReviewStrong Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Strong Evidence
Sample
N=not applicable
Participants
Adults with obesity across reviewed clinical trials and real-world studies

What This Study Found

Review of obesity pharmacotherapy advancements and challenges covers GLP-1/GIP drugs, emerging agents, access barriers, and the evolving treatment landscape.

Key Numbers

Review covers the global increase in obesity prevalence and the expanding pharmacotherapy options available to address it.

How They Did This

Methodology in publication.

Why This Research Matters

Relevant to peptide-based therapeutic applications.

The Bigger Picture

Contributes to peptide therapeutic evidence.

What This Study Doesn't Tell Us

Limitations in publication.

Questions This Raises

  • ?Long-term implications?
  • ?Comparison to evidence?
  • ?Next research?

Trust & Context

Key Stat:
Key finding Review of obesity pharmacotherapy advancements and challenges covers GLP-1/GIP drugs, emerging agent
Evidence Grade:
Based on study design.
Study Age:
Published in 2025.
Original Title:
Advancements and challenges in the management of obesity using pharmacotherapy (Review).
Published In:
Experimental and therapeutic medicine, 30(2), 162 (2025)
Database ID:
RPEP-09897

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

What does this mean?

Review of obesity pharmacotherapy advancements and challenges covers GLP-1/GIP drugs, emerging agents, access barriers, and the evolving treatment landscape.

How reliable?

Consult publication and provider.

Read More on RethinkPeptides

Cite This Study

RPEP-09897·https://rethinkpeptides.com/research/RPEP-09897

APA

Alotaibi, Saqer S; Eldrehmy, Essam H; Albogami, Sarah M; Alkhedaide, Adel; Dahab, Omima. (2025). Advancements and challenges in the management of obesity using pharmacotherapy (Review).. Experimental and therapeutic medicine, 30(2), 162. https://doi.org/10.3892/etm.2025.12912

MLA

Alotaibi, Saqer S, et al. "Advancements and challenges in the management of obesity using pharmacotherapy (Review).." Experimental and therapeutic medicine, 2025. https://doi.org/10.3892/etm.2025.12912

RethinkPeptides

RethinkPeptides Research Database. "Advancements and challenges in the management of obesity usi..." RPEP-09897. Retrieved from https://rethinkpeptides.com/research/alotaibi-2025-advancements-and-challenges-in

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.